Zinbryta (Daclizumab) for Multiple Sclerosis | MyMSTeam

Connect with others who understand.

sign up Log in
About MyMSTeam
Powered By

On March 2, 2018, manufacturers Biogen and AbbVie announced that they were withdrawing Zinbryta (Daclizumab) from the market worldwide. The drug is no longer available.

For more details about this treatment, visit:
Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA (daclizumab) for Relapsing Multiple Sclerosis - Biogen

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in